表紙
市場調查報告書
商品編碼
991898

全球單株抗體市場(2021年-2025年)

Global Monoclonal Antibodies Market 2021-2025

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球單株抗體的市場規模在2021年∼2025年間,預測將成長到634億1000萬美元,在預測期間內預計將以8%的年複合成長率增長。

市場成長的主要因素有低價格的生物相似藥與單株抗體標靶治療作用機制的引進。

本報告提供單株抗體市場調查,提供市場概要,市場成長要素及阻礙因素分析,各用途·各類型·各地區的市場規模的變化與預測,供應商分析,市場機會等全面性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模2019
  • 市場預測:從2019年∼2024年的預測

波特的五力分析

各用途市場市場區隔

  • 市場·市場區隔
  • 各用途比較
  • 腫瘤學-市場規模與預測(2019年∼2024年)
  • 自體免疫疾病-市場規模與預測(2019年∼2024年)
  • 感染疾病-市場規模與預測(2019年∼2024年)
  • 其他的用途-市場規模與預測(2019年∼2024年)
  • 各用途的市場機會

各類型的市場區隔

  • 單株抗體的各類型市場區隔

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美-市場規模與預測(2019年∼2024年)
  • 歐洲-市場規模與預測(2019年∼2024年)
  • 亞洲-市場規模與預測(2019年∼2024年)
  • 其他地區-市場規模與預測(2019年∼2024年)
  • 主要的主要國家
  • 地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 競爭模式
  • 業者情勢
  • 創造性破壞狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

附錄

目錄
Product Code: IRTNTR44342

Technavio has been monitoring the monoclonal antibodies market and it is poised to grow by $ 63.41 bn during 2021-2025 progressing at a CAGR of 8% during the forecast period. Our report on monoclonal antibodies market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the introduction of low-priced biosimilar monoclonal antibodies and targeted therapeutic mechanism of action. In addition, introduction of low-priced biosimilar monoclonal antibodies is anticipated to boost the growth of the market as well.

The monoclonal antibodies market analysis includes application segment and geographical landscapes.

Technavio's monoclonal antibodies market is segmented as below:

By Application

  • Oncology
  • Autoimmune disorders
  • Infectious diseases
  • Other applications

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the strong R&D pipeline as one of the prime reasons driving the monoclonal antibodies market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on monoclonal antibodies market covers the following areas:

  • Monoclonal antibodies market sizing
  • Monoclonal antibodies market forecast
  • Monoclonal antibodies market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading monoclonal antibodies market vendors that include AbbVie Inc., AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA. Also, the monoclonal antibodies market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Application

  • Market segments
  • Comparison by Application
  • Oncology - Market size and forecast 2019-2024
  • Autoimmune disorders - Market size and forecast 2019-2024
  • Infectious diseases - Market size and forecast 2019-2024
  • Other applications - Market size and forecast 2019-2024
  • Market opportunity by Application

Market Segmentation by Type

  • Segmentation by type of monoclonal antibodies

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Competitive Scenario
  • Vendor Landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ billion)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Application - Market share 2020-2025 (%)
  • 22: Comparison by Application
  • 23: Oncology - Market size and forecast 2020-2025 ($ billion)
  • 24: Oncology - Year-over-year growth 2020-2025 (%)
  • 25: Autoimmune disorders - Market size and forecast 2020-2025 ($ billion)
  • 26: Autoimmune disorders - Year-over-year growth 2020-2025 (%)
  • 27: Infectious diseases - Market size and forecast 2020-2025 ($ billion)
  • 28: Infectious diseases - Year-over-year growth 2020-2025 (%)
  • 29: Other applications - Market size and forecast 2020-2025 ($ billion)
  • 30: Other applications - Year-over-year growth 2020-2025 (%)
  • 31: Market opportunity by Application
  • 32: Customer landscape
  • 33: Market share by geography 2020-2025 (%)
  • 34: Geographic comparison
  • 35: North America - Market size and forecast 2020-2025 ($ billion)
  • 36: North America - Year-over-year growth 2020-2025 (%)
  • 37: Europe - Market size and forecast 2020-2025 ($ billion)
  • 38: Europe - Year-over-year growth 2020-2025 (%)
  • 39: Asia - Market size and forecast 2020-2025 ($ billion)
  • 40: Asia - Year-over-year growth 2020-2025 (%)
  • 41: ROW - Market size and forecast 2020-2025 ($ billion)
  • 42: ROW - Year-over-year growth 2020-2025 (%)
  • 43: Key leading countries
  • 44: Market opportunity by geography ($ billion)
  • 45: Impact of drivers and challenges
  • 46: Vendor landscape
  • 47: Landscape disruption
  • 48: Industry risks
  • 49: Vendors covered
  • 50: Market positioning of vendors
  • 51: AbbVie Inc. - Overview
  • 52: AbbVie Inc. - Business segments
  • 53: AbbVie Inc. - Key offerings
  • 54: AbbVie Inc. - Key customers
  • 55: AbbVie Inc. - Segment focus
  • 56: AstraZeneca Plc - Overview
  • 57: AstraZeneca Plc - Product and service
  • 58: AstraZeneca Plc - Key offerings
  • 59: AstraZeneca Plc - Key customers
  • 60: AstraZeneca Plc - Segment focus
  • 61: Bristol-Myers Squibb Co. - Overview
  • 62: Bristol-Myers Squibb Co. - Product and service
  • 63: Bristol-Myers Squibb Co. - Key offerings
  • 64: Bristol-Myers Squibb Co. - Key customers
  • 65: Bristol-Myers Squibb Co. - Segment focus
  • 66: F. Hoffmann-La Roche Ltd. - Overview
  • 67: F. Hoffmann-La Roche Ltd. - Business segments
  • 68: F. Hoffmann-La Roche Ltd. - Key offerings
  • 69: F. Hoffmann-La Roche Ltd. - Key customers
  • 70: F. Hoffmann-La Roche Ltd. - Segment focus
  • 71: GlaxoSmithKline Plc - Overview
  • 72: GlaxoSmithKline Plc - Business segments
  • 73: GlaxoSmithKline Plc - Key offerings
  • 74: GlaxoSmithKline Plc - Key customers
  • 75: GlaxoSmithKline Plc - Segment focus
  • 76: Johnson & Johnson - Overview
  • 77: Johnson & Johnson - Business segments
  • 78: Johnson & Johnson - Key offerings
  • 79: Johnson & Johnson - Key customers
  • 80: Johnson & Johnson - Segment focus
  • 81: Merck & Co. Inc. - Overview
  • 82: Merck & Co. Inc. - Business segments
  • 83: Merck & Co. Inc. - Key offerings
  • 84: Merck & Co. Inc. - Key customers
  • 85: Merck & Co. Inc. - Segment focus
  • 86: Novartis AG - Overview
  • 87: Novartis AG - Business segments
  • 88: Novartis AG - Key offerings
  • 89: Novartis AG - Key customers
  • 90: Novartis AG - Segment focus
  • 91: Pfizer Inc. - Overview
  • 92: Pfizer Inc. - Business segments
  • 93: Pfizer Inc. - Key offerings
  • 94: Pfizer Inc. - Key customers
  • 95: Pfizer Inc. - Segment focus
  • 96: Sanofi SA - Overview
  • 97: Sanofi SA - Business segments
  • 98: Sanofi SA - Key offerings
  • 99: Sanofi SA - Key customers
  • 100: Sanofi SA - Segment focus
  • 101: Currency conversion rates for US$
  • 102: Research Methodology
  • 103: Validation techniques employed for market sizing
  • 104: Information sources
  • 105: List of abbreviations